The Negative Effect of Triple-Negative Breast Cancer on Outcome after Breast-Conserving Therapy

被引:36
|
作者
Zaky, Sandra S. [1 ]
Lund, MaryJo [2 ,3 ,4 ]
May, Kelly A. [5 ]
Godette, Karen D. [1 ]
Beitler, Jonathan J. [1 ]
Holmes, Leslie R. [1 ]
O'Regan, Ruth M. [5 ]
Yu, Esther S. [1 ]
Yu, David S. [1 ]
Landry, Jerome C. [1 ]
机构
[1] Emory Univ, Winship Canc Ctr, Dept Radiat Oncol, Atlanta, GA 30322 USA
[2] Emory Univ, Winship Canc Ctr, Emory Sch Med, Atlanta, GA 30322 USA
[3] Emory Univ, Winship Canc Ctr, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA
[4] Emory Univ, Winship Canc Ctr, Rollins Sch Publ Hlth, Dept Hematol Oncol Joint, Atlanta, GA 30322 USA
[5] Emory Univ, Winship Canc Ctr, Dept Med Hematol Oncol, Atlanta, GA 30322 USA
关键词
AFRICAN-AMERICAN; SURVIVAL; RECURRENCE; SUBTYPES; PATTERNS; SURGERY; WOMEN; RISK;
D O I
10.1245/s10434-011-1669-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. To evaluate disease failure patterns and overall survival (OS) of women with triple-negative (TN) breast cancer who underwent breast-conserving therapy (BCT) and to understand the relationship of TN tumors with other prognostic factors. Patients and Methods. The Surveillance, Epidemiology, and End Results (SEER) registry identified 562 women diagnosed and/or treated with unilateral invasive breast cancer during 2003-2004 at three Emory hospitals. After medical record review, 193 eligible women, with all tumor types, received BCT. Primary endpoints (local, regional, and distant recurrences) and secondary endpoint (OS) were evaluated using chi-square tests and Cox proportional hazards models. Results. Of the 193 women, 33 (17.1%) had TN tumors and 160 (82.9%) had non-TN tumors. Patient characteristics were similar between the two tumor types; however, tumor grade and use of chemotherapy and hormones differed between the two groups. Median follow-up was 3.4 years; 22 patients had recurrence (12.2%), and 12 died (6.2%). Patients with TN tumors had higher local (12% versus 4% for non-TN) and distant recurrences (15% versus 4% for non-TN) rates (p = 0.01). On multivariate survival analyses, TN status [hazard ratio (HR) 1.8, 95% confidence interval (CI) 1.13-2.93] and African American (AA) race (HR 1.9, 95%CI 1.2-3.07) were independent predictors of inferior OS. Conclusions. Patients with TN breast cancer showed significant increases in local and distant metastatic recurrence rates after BCT, and TN status and AA race were independent negative predictors of survival. For the future, identification of these high risk features may bring personalized medicine closer to reality.
引用
收藏
页码:2858 / 2865
页数:8
相关论文
共 50 条
  • [41] Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy
    Kim, Sanghwa
    Park, Hyung Seok
    Kim, Jee Ye
    Ryu, Jegyu
    Park, Seho
    Kim, Seung Il
    [J]. YONSEI MEDICAL JOURNAL, 2016, 57 (05) : 1192 - 1198
  • [42] Triple-negative breast cancer and the potential for targeted therapy
    Jhan, Jing-Ru
    Andrechek, Eran R.
    [J]. PHARMACOGENOMICS, 2017, 18 (17) : 1595 - 1609
  • [43] Progress in systemic therapy for triple-negative breast cancer
    Hongnan Mo
    Binghe Xu
    [J]. Frontiers of Medicine., 2021, 15 (01) - 10
  • [44] Anxious Personality and Breast Cancer: Possible Negative Impact on Quality of Life After Breast-Conserving Therapy
    van der Steeg, Alida F. W.
    De Vries, Jolanda
    Roukema, Jan A.
    [J]. WORLD JOURNAL OF SURGERY, 2010, 34 (07) : 1453 - 1460
  • [45] Anxious Personality and Breast Cancer: Possible Negative Impact on Quality of Life After Breast-Conserving Therapy
    Alida F. W. van der Steeg
    Jolanda De Vries
    Jan A. Roukema
    [J]. World Journal of Surgery, 2010, 34 : 1453 - 1460
  • [46] Subtyping of Triple-Negative Breast Cancer: Implications for Therapy
    Abramson, Vandana G.
    Lehmann, Brian D.
    Ballinger, Tarah J.
    Pietenpol, Jennifer A.
    [J]. CANCER, 2015, 121 (01) : 8 - 16
  • [47] Progress in systemic therapy for triple-negative breast cancer
    Mo, Hongnan
    Xu, Binghe
    [J]. FRONTIERS OF MEDICINE, 2021, 15 (01) : 1 - 10
  • [48] Directed Therapy of Subtypes of Triple-Negative Breast Cancer
    Carey, Lisa A.
    [J]. ONCOLOGIST, 2010, 15 : 49 - 56
  • [49] Personalized targeted therapy in triple-negative breast cancer
    Ueno, Naoto T.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 20 - 20
  • [50] New Vaccine Therapy for Triple-Negative Breast Cancer
    Harris, Paul E.
    Rubsamen, Reid
    [J]. CURRENT BREAST CANCER REPORTS, 2024, 16 (03) : 288 - 301